Celltrion Pharm announced on the 14th that its revenue for the second quarter of this year increased by 12.1% year-on-year to 131.3 billion won, while its operating profit surged 64.8% during the same period to 15.5 billion won.
The operating profit margin increased by 4 percentage points to 11.8%, indicating improved revenue. Cumulative revenue for the first half of the year reached 243.8 billion won, and operating profit increased by 100.3% to 26.2 billion won compared to the same period last year.
In particular, revenue from biosimilars significantly increased, driving performance growth.
Looking at the revenue by institutional sector for the second quarter, revenue from the chemical sector was recorded at 66.3 billion won. Major products included the soy sauce agent 'Godekx', which increased by 6.9% year-on-year to 16 billion won, and the hypertension treatment 'Dilatrend', which grew 7% during the same period to 15.1 billion won. Revenue from the diabetes treatment 'Nesina' was 6.4 billion won, which surged 65.7% year-on-year due to production internalization effects.
Revenue from the biosimilar sector reached 32.5 billion won, a 58.3% increase. Sales of Celltrion's autoimmune disease treatment 'Remsima,' the breast cancer and stomach cancer treatment 'Herzuma,' and the blood cancer treatment 'Truxima' amounted to 18.8 billion won. Revenue from 'Uplyma' and 'Vegzelma' increased by 129.4% and 125.5%, respectively, compared to the same period last year. The company noted that the total revenue from new products launched this year amounted to 9.7 billion won, contributing to performance growth.
The contract manufacturing sector recorded a revenue increase of 24.6% year-on-year to 23.2 billion won, supported by the expansion of commercial production of 'Remsima SC' and 'Uplyma.'
Celltrion Pharm plans to strengthen both revenue growth and profitability through strategies such as expanding biosimilar production, enhancing the competitiveness of internalized products, and enlarging contract manufacturing, while increasing market competitiveness through active research and development investment.
A company official said, "Thanks to stable growth in sales of existing products and the full-scale launch of new products, we achieved the largest second-quarter performance ever," and added, "We will strengthen the competitiveness of our key items and maintain a stable production base to continue our consistent results."